Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Long-Term, Open-Label, Multi-Center, Extension Study Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00501293 is registered in ClinicalTrials.gov with Noven Therapeutics as lead sponsor.

NCT NCT00501293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00501293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Long-Term, Open-Label, Multi-Center, Extension Study Designed to Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Lead sponsor
Noven Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2007
Completion date
February 28, 2009
Enrollment
163 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

adhd